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While emerging evidence indicates that dendritic cells (DC) play a central role in the pathogenesis of multiple sclerosis (MS), their







) treatment ofmonocyte-derivedDC results in a semimature phenotype and anti-inflammatory










-treated immature DC could be recovered with a 78% yield and 75% viability. Cryopreservation did not affect the




-treated DC nor their capacity to induce T cell hyporesponsiveness. In addition,




-treated DC is antigen-specific and robust since T cells retain their capacity
to respond to an unrelated antigen and do not reactivate upon rechallenge with fully mature conventional DC, respectively.
These observations underline the clinical potential of tolerogenic DC (tolDC) to correct the immunological imbalance in MS.
Furthermore, the feasibility to cryopreserve highly potent tolDC will, ultimately, contribute to the large-scale production and the
widely applicable use of tolDC.
1. Introduction
Multiple sclerosis (MS) is a chronic inflammatory and neu-
rodegenerative disease of the central nervous system (CNS)
characterized by disseminated patches of demyelination and
axonal loss in the brain and spinal cord. Although both
genetic [1] and environmental [2] factors have been demon-
strated to contribute to the onset of disease, it is currently
generally accepted thatMS is a T helper type 1 (Th1) andTh17-
driven immune-mediated disease. This was demonstrated by
immune cell infiltration and accompanying inflammatory
processes leading to damage of myelin [3, 4]. Moreover,
Th1 and Th17 lineage-specific cytokines, interferon-𝛾 (IFN-
𝛾), and interleukin-17 (IL-17) play a pivotal role in the
pathogenesis of MS. Production of IFN-𝛾 and IL-17 by T cells
has been associated with disease activity in MS patients [4]
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and these cytokines are also expressed in brain lesions [5, 6].
Several clinical trials have been performed to determine if
targeting effector T cells may be beneficial for MS patients.
In particular, anti-IFN-𝛾 therapy showed promising results
in a small clinical trial in MS [7] but was not beneficial in
experimental autoimmune encephalomyelitis (EAE), an ani-
mal model of MS. Hence, since IFN-𝛾 and IL-17 are probably
not the critical determinants of whether an effector T cell is
capable of trafficking to the CNS and inducing inflammatory
demyelination, the focus of research on effector T cells in MS
should be on upstream pathways driving Th1 and Th17 cells.
In this perspective, dendritic cells (DC), professional antigen-
presenting cells, play an important role in polarizing the T cell
response, thereby regulating the balance between immunity
and tolerance. The possibility of modulating the function of
DCusing various biological or pharmacological agentsmakes
DC interesting not only from an immunopathogenic point of
view but also from a therapeutic perspective [8].
The identification of so-called tolerogenic, that is,
tolerance-inducing, DC (tolDC) has paved the way for novel
forms of cell-based tolerance-inducing therapies (CTT).
TolDC can be characterized by low expression levels of cos-
timulatory molecules, low production of proinflammatory
cytokines, high secretion of anti-inflammatory cytokines, and
a maturation-resistant phenotype [9, 10]. Importantly, tolDC
can inhibit or suppress T cell responses via a multitude of
mechanisms, including T cell deletion, T cell anergy, cytokine
deviation, and/or the induction of regulatory T cells (Treg)
[11]. In doing so, tolDC can reprogramme or modulate the
immune system in order to reestablish self-tolerance in auto-
immunity.
Various immunomodulatory strategies have been used
to generate tolDC in vitro. In this respect, an exponentially
increasing amount of studies is currently investigating the







active form of vitamin D
3
[12–15]. Increasing evidence has










modulate both innate and adaptive immune responses [16,





renders DC in a semimature state, as evi-
denced by low expression levels of costimulatory molecules,
such as CD40, CD80, and CD86, increased IL-10 production,





treated DC display a reduced capacity to activate T cells
[12–14, 18] and promising results were obtained following
their administration in preclinical models of autoimmunity
[15, 19–21].
So far, the first clinical trials evaluating the use of tolDC
have been recently completed for type 1 diabetes, rheumatoid
arthritis, and Crohn’s disease [22–25]. The results were pro-
mising and the use of tolDC was safe and well tolerated.
Nevertheless, several challenges still remain. First, it can
be envisaged that, following migration to the inflamed tis-
sues in vivo, clinically administered tolDC may acquire an
immunostimulatory state upon encounter of inflammatory
mediators. Hence, a stable maturation-resistant phenotype
of tolDC should be aimed for. Similarly, tolDC-mediated
T cell hyporesponsiveness should be persistent and robust
following in vivo rechallenge with proinflammatory stimuli.
Moreover, T cell hyporesponsiveness should be directed to
disease-specific antigens, while preserving T cell capacity
to respond to unrelated antigens. Other remaining issues
are dose, timing, route, and frequency of administration of
tolDC. Regarding the latter, it was recently demonstrated that
althoughmurine tolDCwere able to reduce disease activity in
EAE, the clinical effectwas transient but could be restored fol-
lowing a subsequent injectionwith tolDC [26] suggesting that
repeated administration is necessary. For this, large numbers
of DCmanufactured in accordance with current goodmanu-
facturing practice (cGMP) guidelines are required. Since the
manufacturing of a large number of DC is time-consuming
and cost-intensive, cryopreservation of tolDC in ready-to-use
aliquots for clinical application would significantly improve
the feasibility of consecutive injections. Moreover, produc-
tion of sufficient numbers of DC at one time point would not
only facilitate the use of DC in clinical trials but also reduce
batch-to-batch variations. Whereas an efficient cryopreser-
vation method for tolDC would greatly contribute to their
use in clinical trials, studies demonstrating the influence of
cryopreservation on the properties of tolDC are scarce.
In the present study, the effects of the active form of
vitamin D
3
on the differentiation, maturation, and function
of monocyte-derived DC (mo-DC) from healthy controls as
well as from MS patients were investigated. Given the risk of
concomitant DC activation in a proinflammatory microen-
vironment in vivo, the in vitro stability of the maturation-
resistant phenotype was also analyzed. Finally and impor-
tantly, we addressed the feasibility to cryopreserve tolDC by
assessing the effects of cryopreservation on the phenotype






2. Material and Methods
2.1. Study Population. Peripheral blood from healthy volun-
teers was obtained from buffy coats provided by the Antwerp
Blood Transfusion Center (Red Cross-Flanders, Edegem,
Belgium). MS patients, diagnosed according to the revised
McDonald criteria [27], were recruited by the Department of
Neurology from the Antwerp University Hospital (Edegem,
Belgium). Ten patients (6 males and 4 females) with an
average age of 38 years (range: 25–52 years) and a median
expanded disability status scale (EDSS) score of 3 (range: 0–
5) were included (Table 1). All subjects gave written consent
after they were informed of the nature and possible risks of
the study. The study was approved by the Ethics Committee
of the Antwerp University Hospital and followed the tenets
of the Declaration of Helsinki. Approximately 100mL of
heparinized bloodwas collected by venous puncture. Samples
were processed within 24 hours after collection.
2.2. Dendritic Cell Culture. Peripheral blood mononuclear
cells (PBMC)were isolated by density gradient centrifugation
(Ficoll-Paque PLUS, GE Healthcare, Chalfont St. Giles,
UK). Next, CD14+ monocytes were purified by CD14+
immunomagnetic selection (CD14 Reagent, Miltenyi Biotec,
Bergisch Gladbach, Germany), according to manufacturer’s
Journal of Immunology Research 3
Table 1: Clinical details of the patients recruited into the study.
UPN Gender Age MS-type EDSS score Disease duration (years) Medication
MS-DC 001 F 51 RR-MS 3 14.5 Glatiramer acetate
MS-DC 002 M 52 SP-MS 5 19 None
MS-DC 003 F 27 CIS 0 1 None
MS-DC 004 M 35 RR-MS 3 2 Natalizumab
MS-DC 005 F 35 RR-MS 3 6 Natalizumab
MS-DC 006 M 33 RR-MS 3.5 14 Natalizumab
MS-DC 007 F 42 RR-MS 2 18 IFN-𝛽
MS-DC 008 M 45 RR-MS 2 19 None
MS-DC 009 M 32 RR-MS 2.5 1 IFN-𝛽
MS-DC 010 M 25 RR-MS 1.5 2 IFN-𝛽





UPN, unique patient number; M, male; F, female; EDSS, expanded disability status scale; RR-MS, relapsing-remitting multiple sclerosis; SP-MS, secondary-
progressive multiple sclerosis; and CIS, clinically isolated syndrome.
instructions, andwere directly used for in vitroDCdifferenti-
ation (Figure 1).The CD14-depleted cell fraction (i.e., periph-
eral blood lymphocytes (PBL)) was cryopreserved in freezing
solution containing 90% fetal bovine serum (Life Technolo-
gies, Paisley, UK) supplemented with 10% dimethyl sulfoxide
(DMSO, Sigma-Aldrich, Bornem, Belgium) and stored at
−80∘C for later use in DC/T cell cocultures. In order to
generate immature conventionalDC,CD14+monocyteswere
cultured at a density of 1–1.2 × 106/mL for 7 days in Iscove’s
modified Dulbecco’s Medium (IMDMwith L-glutamine, Life
Technologies) supplemented with 10 𝜇g/mL gentamicin (Life
Technologies), 1 𝜇g/mL amphotericin B (Life Technologies),
2.5% heat-inactivated human (h) AB serum (Life Tech-
nologies), 25 ng/mL IL-4 (Gentaur, Brussels, Belgium), and
17.5 ng/mL granulocyte macrophage colony-stimulating fac-
tor (GM-CSF, Gentaur). Simultaneously, tolDC were differ-





(Sigma-Aldrich). Cells were replenished
on day 3 with fresh medium and cytokines. On day 6,
DC were (i) stimulated for 24 hours by adding a cocktail
of proinflammatory cytokines consisting of 100U/mL IL-1𝛽
(Biosource Europe, Nivelles, Belgium), 500U/mL IL-6 (Life
Technologies), 2.5 ng/mL tumor necrosis factor-𝛼 (TNF-







, Pfizer, Elsene, Belgium) (i.e., cytokine cocktail-matured
DC (cc-mDC)), or (ii) stimulated for 24 hours by adding
1 𝜇g/mL lipopolysaccharide (LPS) (Invivogen, SanDiego, CA,
USA) and 1000 IU/mL IFN-𝛾 (ImmunoTools, Friesoythe,
Germany) (i.e., LPS-matured DC (LPS-mDC)), or (iii) left
untreated (i.e., immature DC (iDC)). Cells were cultured in
a humidified atmosphere with 5% CO
2





-treated DC were harvested
and used in further experiments.
2.3. Cryopreservation and Thawing Conditions. On day 7,





resuspended in freezingmediumcontaining 86%hAB serum,
10% DMSO, and 4% glucose and frozen in 2mL cryotubes
(Sarstedt, Numbrecht, Germany) at a concentration of
107 cells/mL. Cell suspensions were slowly frozen at a cooling
rate of −1∘C/min to −80∘C by using a Mr. Frosty freezing
container (Nalgene, Rochester, USA). Within 4 days, cell
suspensions were transferred to liquid nitrogen for long-
term storage. Frozen samples were quickly thawed at 37∘C
in a warm water bath and subsequently transferred into
preheated (37∘C) CellGro medium (CellGenix, Freiburg,
Germany) supplemented with 1% hAB serum. Next, cells
were washed and resuspended in preheated CellGro medium
supplemented with 1% hAB serum, 25 ng/mL IL-4, and
17.5 ng/mL GM-CSF. Following a 2 h resting phase at 37∘C





-treated iDC were stimulated with a proinflam-
matory cytokine cocktail or left untreated. After 24 hours,
cells were harvested and used in further experiments.
2.4. Flow Cytometric Immunophenotyping. For phenotypic
characterization of DC, direct immunofluorescence staining
was performed using the following fluorochrome-labeled
mouse anti-human monoclonal antibodies: anti-CD86-fluo-
rescein isothiocyanate (FITC) (BD Pharmingen, Erembodegem,
Belgium), anti-CD80-phycoerythrin (PE) (BD Biosciences,
Erembodegem, Belgium), anti-human leukocyte antigen-
(HLA-) DR-peridinin chlorophyll (PerCP) (BD Biosciences),
anti-CD83-FITC (Life Technologies), anti-dendritic cell-spe-
cific intercellular adhesionmolecule-3-grabbing nonintegrin-
(DC-SIGN-) PE (BD Pharmingen), anti-CD14-PerCP (BD
Biosciences), anti-programmeddeath-ligand 1- (PD-L1-) FITC
(BD Pharmingen), anti-CCR7-PE (R&D Systems, Abingdon,
UK), and anti-immunoglobulin-like transcript 3- (ILT3-) PE-
Cy5 (Immunotech, Marseille, France). Isotype-matched con-
trol monoclonal antibodies were used to determine non-
specific background staining. Propidium iodide staining was
done for analysis of cell viability. For analytical flow cytome-
try, at least 104 events were analyzed using a BDFACScan flow
cytometer (BD Biosciences). All results were analyzed using
FlowJo software (Tree Star, Ashland, USA).
4 Journal of Immunology Research
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Figure 1: Experimental design. CD14+ monocytes were cultured for 6 days in the presence of IL-4 and GM-CSF or in the presence of IL-








-treated iDC, respectively. On day 6, iDC were
stimulated with a cocktail of proinflammatory cytokines (i.e., cc-matured DC (cc-mDC)) or with LPS and IFN-𝛾 (i.e., LPS-matured DC
(LPS-mDC)) or left untreated (i.e., iDC).
2.5. Cytokine Release Assays. For quantitative detection of
the cytokine secretion profile of the different DC popula-
tions, a multiplex fluorescent bead immunoassay (IL-1𝛽, IL-
2, IL-4, IL-5, IL-6, IL-8, IL-10, IL-12p70, TNF-𝛼, TNF-𝛽,
and IFN-𝛾) (Bender MedSystems, Vienna, Austria) and a
transforming growth factor-𝛽 (TGF-𝛽) ELISA (eBioscience,
San Diego, United States of America) were used according to
themanufacturer’s instructions. For this, iDC andmDCwere
harvested, washed, and resuspended in IMDMsupplemented
with 5% hAB serum at a concentration of 5 × 105 cells/mL.
After 24 hours, supernatant was collected for analysis of
cytokine production.
2.6. Allogeneic Mixed Lymphocyte Reaction (Allo-MLR). In
order to assess the allogeneic T cell-stimulatory capacity
of DC, DC were cocultured with allogeneic responder PBL
at a 1 : 10 ratio. Nonstimulated responder PBL served as
negative control, while allogeneic responder cells stimulated
with mitomycin C-treated (Sigma-Aldrich) PBL were used
as positive control. Cocultures were performed in IMDM
supplemented with 5% hAB serum at 37∘C. After 6 days, the
secreted level of IFN-𝛾 in the cell culture supernatant was
determined as a measure for allostimulatory capacity using
a commercially available ELISA kit (PeproTech, New Jersey,
USA), where each condition is measured in triplicate.
2.7. Antigen-Specific T Cell-Stimulatory Capacity of DC. In
order to determine the antigen-specific T cell-stimulatory
capacity of DC, 5 × 106 PBL were stimulated with a pool
of myelin-derived peptides (5𝜇g/mLmyelin oligodendrocyte
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glycoprotein (MOG) (aa 1–22), 5 𝜇g/mL MOG (aa 34–56),
5 𝜇g/mL MOG (aa 64–86), and 5 𝜇g/mL MOG (aa 74–
96) and 5 𝜇g/mL myelin basic protein (MBP) (aa 84–102)
and 5 𝜇g/mL MBP (aa 143–168), all purchased from Severn
Biotech Ltd. (Kidderminster, UK)) in the presence or absence
of 5 × 105 autologous DC. After 7 days of coculture, PBL were
analyzed for antigen-specific responsiveness by determin-
ing IFN-𝛾 production following antigenic restimulation by
means of IFN-𝛾 ELISPOT (Mabtech, Nacka Strand, Sweden),
according to the manufacturer’s instructions. In brief, 2 × 105
stimulated PBL were rechallenged with 5 𝜇g/mL of MOG-
and MBP-derived peptides in anti-IFN-𝛾 antibody-coated
96-well polyvinylidene fluoride (PVDF) plates (Millipore,
Bedford, MA, USA). Nonstimulated PBL were used as a con-
trol and each condition was measured in quadruple. In some
experiments, PBL were harvested on day 7 of coculture and
restimulated either with 0.5𝜇g/mL cytomegalovirus (CMV)
pp65-derived peptide pool or with 5 𝜇g/mL of MOG- and
MBP-derived peptides combined with cryopreserved fully
mature conventional DC of the same donor. Frequencies of
antigen-specific IFN-𝛾-secreting cells were calculated based
on the number of spots counted using an automated AID
ELISPOT Reader system (AIDGmbH, Strassberg, Germany)
and analyzed using AID ELISPOT software version 5.0. A
positive responder was defined according to the guidelines
of the ELISPOT proficiency panel from the Cancer Vaccine
Consortium [28]: per 106 PBL, themean antigen-specific spot
count for a donor and condition must be greater than or
equal to 15 spots per well and at least 2.5 times as high as the
background reactivity.
2.8. DC-Mediated Induction of Suppressive T Cell Populations.
The induction of different populations of Treg was deter-
mined following coculture of autologous PBL, stimulated
with MOG- and MBP-derived peptides in the presence or
absence of DC, as described above. At day 6, 10 𝜇g/mL
brefeldin A (GolgiStop, BD Pharmingen) was added to the
DC/T cell coculture and incubated overnight at 37∘C. Next,
cells were harvested and membrane markers were stained
with the following mouse anti-human monoclonal anti-
bodies: anti-CD3-PerCP-Cy5.5 (BD Biosciences), anti-CD4-
allophycocyanin-H7 (anti-CD4-APC-H7) (BD Biosciences),
anti-CD8-Pacific Blue (Life Technologies), and anti-CD25-
PE-Cy7 (BD Biosciences). Subsequently, cells were fixed and
permeabilized using a FOXP3 Staining Buffer Kit (eBiosci-
ence,Hatfield,UK), according tomanufacturer’s instructions,
and intracellular markers were stained with anti-FOXP3-
alexa488 (BD Pharmingen), anti-TGF-𝛽-PE (IQ Products,
Groningen, Netherlands), and anti-IL-10-APC (BDPharmin-
gen). Labeled cells were analyzed on a Cyflow ML flow
cytometer (Partec, Münster, Germany). For analytical flow
cytometry, at least 5 × 104 CD3+ CD4+ CD8− lymphocytes
were acquired.All resultswere analyzed using FlowJo software.
2.9. Statistical Analysis. Results are expressed as mean ±
standard error of mean (SEM), unless stated otherwise.
Comparisons were validated using one-way or two-way
analysis of variance (ANOVA) with a Bonferroni post hoc
test for pairwise group comparisons, when appropriate using
GraphPad version 5 software (Prism, La Jolla, CA, USA). A p
value of ≤0.05 was considered as statistically significant.
3. Results
3.1. 1,25(OH)2D3-Treated Immature DC Express Lower Levels
of CD86 and HLA-DR and Display an Anti-Inflammatory
Cytokine Profile as Compared to Conventional DC. Previ-
ously, we reported no major differences in the phenotype of
in vitro generated immature DC of MS patients as compared
to those of healthy controls, except for the expression of





treatment of immature mo-DC from healthy
controls results in significantly lower expression levels of





-treated mo-DC from MS patients only
show lower expression levels of HLA-DR as compared to
conventional mo-DC (Figures 2(a) and 2(c)). However, it
needs to be noted that immature conventional DC of healthy
controls show a significantly higher expression level of CD86
as compared to those of MS patients. MS-derived mo-










-treated mo-DC from MS patients
display significantly higher expression levels of DC-SIGN
as compared to those of healthy controls (Supplementary
Figure 1, in Supplementary Material available online at
http://dx.doi.org/10.1155/2016/5392623). No differences for





treatment ofmo-DC fromboth healthy controls





treatment did not affect the expression of CD14,
of the chemokine receptor CCR7, and of the inhibitory
molecules PD-L1 and ILT-3 by mo-DC from both healthy
controls and MS patients (Supplementary Figure 1).






from healthy controls and MS patients was assessed using
a multiplex immunoassay and ELISA. No major differences
regarding the cytokine secretion profile of mo-DC from MS
patients as compared to mo-DC from healthy controls could
be detected (Figures 2(e)–2(j)). Remarkably, immature DC
from healthy controls as well as from MS patients produced





to conventional DC (Figure 2(j)).
3.2. 1,25(OH)2D3-Treated DC Display a Semimature Pheno-
type. Next, immaturemo-DCwere stimulatedwith a cocktail
of proinflammatory cytokines (i.e., cc-mDC) for 24 hours.
Conventional DC of both healthy controls (Table 2(a)) and
MS patients (Table 2(b)) acquire a mature phenotype follow-
ing activation with proinflammatory stimuli, as evidenced by
upregulation of the expression of CD80, CD86, CD83, and





DC from both healthy controls and MS patients displayed
a significantly lower expression of CD86, CD83, and HLA-
DR upon stimulation with a proinflammatory cytokine





-treated DC underwent a maturation process































































































































































































Figure 2: Characterization of in vitro differentiated iDC from healthy controls and MS patients. CD14+ monocytes were cultured for 7 days









-treated iDC (filled triangles), respectively. The expression of (a) CD86, (b) CD80, (c) HLA-DR, and (d) CD83 by DC of healthy
controls (𝑛 = 7) andMS patients (𝑛 = 10) is determined by flow cytometry. Cytokine secretion of (e) IL-1𝛽, (f) IL-6, (g) TNF-𝛼, (h) IL-12p70,




-treated iDC is determined by a multiplex immunoassay or ELISA. Horizontal
lines show the mean. MFI, mean fluorescence intensity, and iDC, immature DC.
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Table 2: Immunophenotypic analysis of in vitro differentiated DC from healthy controls and MS patients upon stimulation with
proinflammatory molecules.
(a) Healthy controls (𝑛 = 7) cc-mDC
Marker Type Fold change (cc-mDC/iDC) MFI ± SD 𝑝 value∗ 𝑝 value∗∗





DC 1.89 232 ± 96 𝑝 < 0.05





DC 1.64 36 ± 18 n.s.





DC 2.03 33 ± 11 n.s.





DC 1.43 86 ± 33 n.s.
(b) MS patients (𝑛 = 10) cc-mDC
Marker Type Fold change (cc-mDC/iDC) MFI ± SD 𝑝 value∗ 𝑝 value∗∗





DC 2.35 194 ± 77 𝑝 < 0.05





DC 1.17 31 ± 9 n.s.





DC 1.76 24 ± 8 n.s.





DC 1.56 117 ± 59 n.s.
CD14+monocytes were cultured for 6 days in the presence of IL-4 and GM-CSF or in the presence of IL-4, GM-CSF, and 1,25(OH)2D3 to obtain conventional
iDC or 1,25(OH)2D3-treated iDC, respectively. On day 6, DC were stimulated with a cocktail of proinflammatory cytokines (i.e., cc-matured DC (cc-mDC))
or left untreated (i.e., iDC).Themean fluorescent intensity (MFI) of costimulatory molecules, CD80 and CD86, of maturation marker, CD83, and of HLA-DR
by various DC subsets of healthy controls (a) (𝑛 = 7) and MS patients (b) (𝑛 = 10) was evaluated. Results are expressed as fold change, calculated as the ratio
between the MFI value of cc-mDC to the MFI value of iDC.
∗The 𝑝 values indicated are calculated for cc-mDC versus iDC.
∗∗The 𝑝 values indicated are calculated for conventional cc-mDC versus cytokine cocktail-matured 1,25(OH)2D3-treated DC.
MFI, mean fluorescence intensity; cc-mDC, cytokine cocktail-matured DC; iDC, immature DC; and n.s., nonsignificant.
as demonstrated by upregulated expression of CD80, CD83,
CD86, and HLA-DR, albeit less pronounced as in conven-
tionalDC.No significant differences could be observed regard-
ing the expression of DC-SIGN, CD14, and the inhibitory





mo-DC and conventional mo-DC following stimulation with
proinflammatory molecules (Supplementary Figure 1).
Additionally, we investigated the cytokine secretion pro-





ing stimulation with proinflammatory molecules. Our find-
ings indicate significantly higher levels of secreted IL-1𝛽, IL-
6, IL-12p70, and TNF-𝛼 by conventional DC of both healthy
controls andMS patients following stimulation with LPS and
IFN-𝛾 (Figure 3(b)). Noteworthy, LPS and IFN-𝛾-stimulated
conventional mo-DC from MS patients secrete significantly
higher, in particular 20-fold more, amounts of IL-12p70 as
compared to conventional mo-DC from healthy controls.
Similarly, also the secretion of IL-1𝛽 and IL-6 by mo-DC
fromMS patients was increased as compared tomo-DC from





DC drastically abrogated the secretion of IL-12p70 and TNF-
𝛼 by mo-DC from both healthy controls and MS patients.
Production of IL-1𝛽 and IL-6 following stimulation with LPS










treatment, mo-DC from MS
patients display a significantly higher secretion of IL-1𝛽, IL-
6, and TNF-𝛼 following stimulation with LPS and IFN-




-treated mo-DC of healthy





-treated mo-DC from either healthy controls
or MS patients. However, following stimulation with LPS
and IFN-𝛾, the secretion of IL-10 by conventional mo-DC










treatment ofmo-DC renders DC of both healthy controls and
MS patients in a semimature state as indicated by a signifi-
cantly impaired upregulation of the expression of costimula-
tory molecules and activation markers as well as by a signifi-
cantly reduced secretion of proinflammatory cytokines.
3.3. Cryopreservation Did Not Affect the Expression of Mem-
brane Markers by 1,25(OH)2D3-Treated DC. In order to
facilitate multiple injections with tolDC for clinical appli-
cations, we evaluated the feasibility to cryopreserve tolDC.
For this, viability, recovery, and phenotype of cryopreserved
iDC were assessed upon thawing. We demonstrate a yield
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Figure 3: Immunophenotypic analysis and cytokine secretion profile of in vitro differentiated DC from healthy controls and MS patients
upon maturation with proinflammatory stimuli. CD14+ monocytes were cultured for 6 days in the presence of IL-4 and GM-CSF or in the








-treated iDC, respectively. On day
6, DC were stimulated with a cocktail of proinflammatory cytokines (i.e., cc-mDC) or with LPS and IFN-𝛾 (i.e., LPS-mDC) or left untreated
(i.e., iDC). (a) Representative example showing immunophenotypic analysis of DC. The expression of CD86, CD80, HLA-DR, and CD83 by




-treated DC is determined by flow cytometry. Immature DC are represented by a solid line, cc-mDC are
represented by a dashed line, and LPS-mDC are represented by a dark grey filled histogram. Isotype-matched controls are represented by the
light grey filled histograms. For analysis, DC were gated on light scatter properties as depicted in the forward scatter (FSC) versus side scatter





-treated DC (black bars) is determined by a multiplex immunoassay or ELISA. Results are expressed as mean ± SEM
(healthy controls: 𝑛 = 7; MS patients: 𝑛 = 10).
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Table 3: Immunophenotypic analysis of in vitro differentiated mo-DC from healthy controls before and after cryopreservation.
Healthy controls (𝑛 = 5) cc-mDC
Marker Type Fold change (cc-mDC/iDC) MFI ± SD 𝑝 value∗ 𝑝 value∗∗





DC 1.19 209 ± 155 n.s.





DC 0.90 22 ± 6 n.s.





DC 1.00 15 ± 4 n.s.





DC 0.92 61 ± 36 n.s.
CD14+ monocytes were cultured for 7 days in the presence of IL-4 and GM-CSF or in the presence of IL-4, GM-CSF, and 1,25(OH)2D3 to obtain immature
conventional DC or 1,25(OH)2D3-treated DC, respectively. On day 7, iDC were frozen and stored at −80
∘C. Next, cryopreserved iDC were thawed, rested for
2 h at 37∘C, and stimulated with a proinflammatory cytokine cocktail for 24 h (i.e., cc-mDC).Themean fluorescent intensity (MFI) of costimulatory molecules,
CD80 and CD86, of maturation marker, CD83, and of HLA-DR by various DC subsets of healthy controls (𝑛 = 5) was determined Results are expressed as fold
change, calculated as the ratio between the MFI value after maturation following a freeze-thaw cycle and the MFI value obtained at immature stage following
a freeze-thaw cycle.
∗The 𝑝 values indicated are calculated for cc-mDC DC after cryopreservation versus iDC after cryopreservation.
∗∗The 𝑝 values indicated are calculated for conventional cc-mDC after cryopreservation versus 1,25(OH)2D3-treated cc-mDC after cryopreservation.
MFI, mean fluorescence intensity; cc-mDC, cytokine cocktail-matured DC; iDC, immature DC; and n.s., nonsignificant.





treated DC following a freeze-thaw cycle (Figure 4(a)). No
significant differences for the yield and viability were found





Furthermore, while conventional iDC display a significantly
increased expression of CD86 and decreased expression
of HLA-DR following cryopreservation, underscoring the
plasticity of the phenotypic characteristics of conventional
DC, no differences regarding the expression levels of HLA-





treated mo-DC following cryopreservation (Figure 4(b)).





iDC to maintain their semimature phenotype after cryop-
reservation, iDC were stimulated with a proinflammatory
cytokine cocktail for 24 hours following a 2 h resting phase
after thawing. Conventional DC display upregulated expres-
sion of CD83 (Table 3). No significant differences were
detected for the expression of HLA-DR, CD80, and CD86,
despite the fact that marked upregulation of CD86 expres-
sion by conventional DC was already observed following
cryopreservation (Figure 4(b)). In addition, cryopreservation





-treated mo-DC, not even upon stimulation
with proinflammatory signals, indicative of a robust semima-




-treated DC (Table 3).
3.4. Allogeneic T Cell-Stimulatory Capacity of 1,25(OH)2D3-
Treated DC before and after Cryopreservation. The immunos-





DC was determined in an allogeneic mixed leukocyte reac-
tion (allo-MLR). For this, responder PBL were stimulated
with allogeneic iDC or mDC of healthy controls at a 10 : 1
ratio.The level of IFN-𝛾 secreted in the coculture supernatant
was used as a measure for allogeneic T cell-stimulatory
capacity. As demonstrated in Figure 5, conventional mo-
DC have profound capacity to stimulate IFN-𝛾-production
by responder PBL in an allo-MLR, which is not affected
by cryopreservation of mo-DC, as compared to the neg-
ative control. In contrast, no allogeneic IFN-𝛾 production





-treated DC, irrespective of thematuration state
of DC. Importantly, this T cell hyporesponsiveness was





-treated iDC or mDC.
3.5. 1,25(OH)2D3-Treated DC Induce Antigen-Specific T Cell
Hyporesponsiveness to Myelin-Derived Antigens. In order to
determine the antigen-specific T cell-stimulatory capacity




-treated DC of healthy
controls (𝑛 = 7) and MS patients (𝑛 = 4), PBL were
stimulated with myelin-derived peptides in the presence or
absence of autologous iDC or mDC at a 10 : 1 ratio for 7
days. Subsequently, the number of antigen-specific IFN-𝛾-
secreting T cells was determined using IFN-𝛾 ELISPOT.
Following rechallenge of in vitro stimulated PBLwithmyelin-
derived peptides, antigen-specific IFN-𝛾 production by PBL
stimulated with conventional mDC was significantly higher
as compared to PBL stimulated with conventional iDC
(Figures 6(a) and 6(b)). Hence, stimulation with fully mature
conventional DC ismandatory to detectmyelin-specific IFN-
𝛾-secreting T cells in both healthy controls and MS patients.
Of interest, there was no significant difference in the number
of MOG/MBP responders between healthy controls and MS
patients. Seven out of 16 healthy controls and 4 out of 7
MS patients displayed a positive myelin-specific response
following stimulation with conventional mDC, as defined in





-treated mDC fail to respond to a rechallenge
with myelin-derived peptides, as evidenced by the signifi-
cantly reduced number of IFN-𝛾-secreting spot-forming cells
as compared to PBL stimulated with conventional mDC
(Figures 6(a) and 6(b)). Based on these observations, we
10 Journal of Immunology Research
Conventional DC
Precryo








% of viability % of recovery
84.1 ± 16.1%
77.9 ± 19.3%1,25(OH)2D3 DC
(a)











































-treated iDC from healthy controls before and









-treated DC, respectively. On day 7, iDC were frozen (i.e., precryo





-treated iDC of healthy controls (𝑛 = 5) was determined on day 7 of DC culture (i.e., precryo) and 26 h after thawing (i.e.,
postcryo). Recovery is expressed as the ratio of cells harvested before and after cryopreservation. (b) The MFI of (A) CD86, (B) CD80, (C)




-treated DC (black bars) of healthy controls (𝑛 = 5) was
determined. Results are expressed as mean ± SEM. MFI, mean fluorescence intensity, and iDC, immature DC.
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Table 4: Flow cytometric analysis of CD4+ CD25hi FOXP3+ Treg and immunosuppressive cytokine-expressing Treg in cultures of PBL





























1.62 ± 0.66 0.17 ± 0.08 0.12 ± 0.02 0.02 ± 0.01 n.s.
∗The 𝑝 values indicated are calculated for MOG- and MBP-derived peptides-stimulated PBL versus PBL cocultured with iDC in the presence of MOG- and
MBP-derived peptides.































treated DC before and after cryopreservation. Fresh and frozen
iDC and mDC were cocultured with allogeneic responder PBL at
a 1 : 10 ratio. Nonstimulated PBL served as negative control, while
allogeneic responder cells stimulated by mitomycin C-treated PBL
(10 : 1 responder/stimulator ratio) were used as positive control.
After 6 days, cell culture supernatant was collected and the secreted
level of IFN-𝛾 was used as a measure for allostimulatory capacity by
means of IFN-𝛾 ELISA. Each condition was measured in triplicate.
Results of healthy controls (𝑛 = 5) are expressed asmean± SEM.The
open bars and black bars represent the measured IFN-𝛾 secretion
before cryopreservation and after cryopreservation, respectively.
iDC, immature DC; cc-mDC, cytokine cocktail-matured DC; and






volunteers andMSpatients induceT cell hyporesponsiveness,
irrespective of the maturation state of DC.





-treated DC is antigen-specific,





-treated DC and myelin-derived peptides to
respond to an unrelated antigen, that is, cytomegalovirus
(CMV) pp65-derived peptides. For this, PBL stimulated with
a pool of myelin-derived peptides in the presence or absence
of iDC or mDC were rechallenged with myelin-derived
peptides or with a CMV pp65-derived peptide pool after 7
days of initial coculture. While a low frequency of myelin-
specific IFN-𝛾-secreting spot-forming cells was detected
when PBL from healthy controls (Figure 6(c)) and from MS
patients (Figure 6(d)) were rechallenged withmyelin-derived
peptides, PBL were still able to secrete IFN-𝛾 production
following rechallengewith a CMVpp65-derived peptide pool
in all conditions tested.
3.6. Mode of Action of T Cell Hyporesponsiveness Mediated by
1,25(OH)2D3-Treated DC. In order to evaluate whether the





DC could be reversed, PBL were stimulated with myelin-





-treated iDC or mDC for 7
days. Next, PBL were rechallenged with myelin-derived pep-
tides alone or withmyelin-derived peptides and conventional
cc-mDC. In both healthy controls (Figure 6(e)) and MS
patients (Figure 6(f)), inclusion of a strong stimulus, such as
fully mature conventional DC, together with antigen rechal-
lenge is associated with a significantly higher number of
antigen-specific IFN-𝛾-secreting T cells as compared to PBL
rechallengedwithmyelin-derived peptides alone. In contrast,





-treated mDC using conventional
cc-mDC did not affect the myelin-specific T cell response.





treated DCwere rendered in a robust hyporesponsive state in
both healthy volunteers and MS patients, irrespective of the
maturation state of DC.
Since others described that CD4+ T cells primed by iDC
acquire a Treg phenotype [30, 31], we assessed the presence
of Treg populations in autologous DC/T cell cocultures.
Hereto, PBL were stimulated with myelin-derived peptides





-treated iDC at a 10 : 1 ratio. After 7 days of
coculture, multiparametric flow cytometry was performed
to characterize the presence of CD4+ CD25+ FOXP3+ Treg
as well as the expression of intracellular immunosuppressive
cytokines. No differences in the number of Treg following





DC could be detected. In addition, we could not observe IL-10
and/or TGF-𝛽-expressing cells (Table 4).
4. Discussion
Current disease-modifying therapies to prevent or slow pro-
gressive disability in MS include IFN-𝛽, glatiramer acetate,
natalizumab, and fingolimod. Recently, a number of new
treatment strategies have been approved for clinical use
by the regulatory authorities including teriflunomide [32],
dimethyl fumarate (BG-12) [33], and alemtuzumab [34]. All
12 Journal of Immunology Research
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-Treated DC induce stable antigen-specific T cell hyporesponsiveness to myelin-derived antigens (MOG/MBP
peptides) in both healthy controls and MS patients. PBL stimulated with MOG/MBP peptides with or without autologous iDC or mDC
were restimulated with MOG/MBP peptides (black bars) after 7 days of initial coculture. Controls represent nonrestimulated PBL (open
bars). The secretion of IFN-𝛾 was used as a measure for autologous T cell-stimulatory capacity. Each condition was measured in quadruple.




-treated DC of healthy controls (𝑛 = 7) and MS





DC was determined for healthy controls (c) and MS patients (d). PBL stimulated with MOG/MBP peptides with or without autologous
DC were restimulated with either MOG/MBP peptides (black bars) or CMV pp65 peptides (dashed bars) after 7 days of initial coculture.




-treated DC of healthy individuals (e) and MS patients (f). PBL
stimulated with MOG/MBP peptides with or without autologous DC were restimulated either with MOG/MBP peptides (black bars) or
with MOG/MBP peptides combined with fully mature conventional DC (blocked bars) after 7 days of initial coculture. iDC, immature DC;
cc-mDC, cytokine cocktail-matured DC; LPS-mDC, lipopolysaccharide-matured DC; PBL, peripheral blood lymphocytes; MOG, myelin
oligodendrocyte glycoprotein; MBP, myelin basic protein; CMV, cytomegalovirus; and SFC, spot forming cells.
are primarily aimed at reducing the number of relapses and
slowing the disease progression; however, none induces a
long-lasting, drug-free remission of MS, whereas several are
accompanied by severe side effects such as secondary autoim-
munity and infections. Therefore, continuous efforts are
aimed at the development of new therapeutic approaches that
specifically target the pathologic autoinflammatory processes
in MS without generalized immune suppression. In this
perspective, the identification of tolDC as cellular mediators
to downmodulate unwanted autoimmune responses may
provide new prospects. Indeed, preclinical evidence from
animal models supports the therapeutic potential of tolDC
as demonstrated by prevention of transplant rejection in
skin and heart graft models [35, 36] or by attenuation of
pathogenic T cells and reestablishment of self-tolerance fol-
lowing administration of ex vivo generated tolDC in collagen-
induced arthritis (CIA), nonobese diabetic (NOD), and EAE
models [15, 19–21]. These promising outcomes resulted in a
number of recently completed phase I clinical trials using
tolDC in patients with type 1 diabetes [22], rheumatoid
arthritis [23, 25], and Crohn’s disease [24]. Treatment with
autologous tolDC was well tolerated and safe without any
discernible adverse events or toxicities. While these stud-
ies highlight the emergence of tolDC therapy as a new
approach to treat autoimmune diseases, numerous questions
still remain in view of the translation of bench findings to the
bedside. Indeed, although different strategies using a variety
of tolerogenic agents for the generation of tolDC in vitro are
showing promising results, not all tolerogenic agents seem to
have the ability to maintain a stable tolerogenic profile, once
administrated in vivo [37].





renders mo-DC in a semimature state as evidenced by
impaired upregulation of the expression of CD86, CD80,
Journal of Immunology Research 13
CD83, andHLA-DR upon stimulation with proinflammatory
molecules as compared to the expression of these markers
by conventional DC. Furthermore, no phenotypic differences











-treated immature DC secrete higher
levels of TGF-𝛽 as well as of IL-6 and TNF-𝛼, as compared





secretion of proinflammatory cytokines following stimula-
tion with LPS and IFN-𝛾 as compared to conventional DC,





treated mo-DC from MS patients. Whereas concomitant
DC activation following administration in an inflammatory
microenvironment in vivo can be envisaged, our findings





from both healthy controls and MS patients, as evidenced
by impaired upregulation of the expression of costimulatory
markers and of the secretion of proinflammatory cytokines
following rechallenge with LPS, in agreement with previous
observations by others [14, 38]. Nevertheless, the levels of
IL-1𝛽, IL-6, and TNF-𝛼 secreted by mature DC of MS
patients are significantly higher as compared to those from










-treated DC in a clinical setting,
for example, for the induction of tolerance in MS patients.
Recently, it was demonstrated that one injection with
murine tolDC in EAE resulted in a profound clinical effect
[26]. However, the clinical improvements were transient
underscoring the possible need for multiple injections with
tolerance-inducing cell products if long-lasting regulation of
the autoimmune response is aimed for. Therefore, cryop-
reservation of DC—allowing the generation of ready-to-use
aliquots—may facilitate the clinical use of tolDC. In addi-
tion, this approach can minimize batch-to-batch variations.
Hence, in order to guarantee the comparability of the cell
product before and after cryopreservation, the function and
phenotype of the DC must be preserved after a freeze-thaw
cycle. Previously, others have described and standardized a
number of approaches to generate immunogenic DC from
cryopreserved monocytes or PBMC [39, 40]. However, the
reported effects of cryopreservation on mo-DC differentia-
tion, function, and allogeneic T cell-stimulatory capacity are
conflicting [41–43]. In addition, frozen PBMC or monocytes
require additional manipulations before a ready-to-use prod-
uct is achieved which is cost-intensive and labor-intensive
and introduces a higher degree of variation in DC charac-
teristics. For this, efforts have been made to cryopreserve
DC. Various reports using DC for cancer immunotherapy
have demonstrated no differences regarding the morphology,
phenotype, and function between cryopreserved and freshly
generated DC [44–47]. However, to date, studies addressing
the influence of cryopreservation on the characteristics of
tolDC are limited.
Here, we report the development and optimization of a
cryopreservation protocol which yielded a recovery of 78%





following a freeze-thaw cycle. Previously, other studies inves-
tigating the effects of cryopreservation on immunostimula-
tory DC demonstrated a recovery of 86% on average [44, 47,
48]. In this study, the recovery of tolDC appears to be lower as
compared to immunostimulatory DC, albeit not statistically





can promote spontaneous apoptosis of mature





and not of the cryopreservation procedure.
Overall, our observations underscore the feasibility to cry-
opreserve tolDC without affecting the viability. Furthermore,
no differences regarding the expression of activationmarkers,





DC could be observed following cryopreservation, indicative





DC. In contrast, conventional DC display increased levels of
CD86 expression and decreased levels ofHLA-DR expression
as compared to freshly generated mo-DC. Similarly, John et
al. have shown that cryopreservation of immature mo-DC
resulted in enhanced cell maturation but decreased endo-
cytic activity and efficiency of adenoviral transduction [48].





mo-DC are unable to activate allogeneic T cells as compared
to conventional DC, irrespective of their maturation state
or cryopreservation. Our study confirms previous findings





-treated DC of both healthy individuals andMS
patients were able to induce T cell hyporesponsiveness fol-






T cells were unable to respond to myelin-derived antigen
rechallenge whereas their ability to respond to an unrelated
antigen was maintained, underlining the potential of tolDC
to induce hyporesponsiveness in an antigen-specific manner.
As clinical translation is aimed for and the need for repetitive
injections of tolDC for a prolonged clinical effect in EAE is
reported [26], the use of cryopreserved tolDC would highly
contribute to the large-scale production and the widely appli-
cable use of tolDC. Recently, the same group reported the in
vivo clinical efficacy of frozen tolDC inEAEas administration
of frozen tolDCwas able to abrogate EAEdisease progression,
mediated by an inhibition of antigen-specific reactivity, the
induction of Treg and regulatory B cells (Breg), and the
activation of immunoregulatory natural killer T (NKT) cells.
Importantly, long-term treatment was well tolerated and
exhibited a prolonged clinical beneficial effect [49].
Although the exact mechanism by which tolDC induce
T cell hyporesponsiveness remains unclear, several mecha-
nisms by which tolDC can induce tolerance and orchestrate T
cell fate have been identified. First, it has been described that
tolDC induce tolerance in a “DC-specific” manner through
the induction of T cell anergy or apoptosis or deletion of
autoreactive T cells. For this, the expression of so-called nega-
tive regulatory molecules has been identified to contribute to
T cell tolerance. Indeed, Unger et al. observed an increased





treated DC contributing to the induction of T cell anergy
[18]. However, in our hands, no pronounced expression of




-treated DC was observed
14 Journal of Immunology Research
as compared to conventional DC (Supplementary Figures 1A





treated DC rendered PBL in a robust hyporesponsive state,
even following rechallenge with fully mature conventional
DC, thereby excluding tolDC-mediated induction of T cell
anergy in agreement with previous reports [14]. VanHalteren





selectively can induce apoptosis in T cells stimulated via
the HLA-peptide complex on the DC surface. Importantly,
bystander T cells, either resting or activated by peptide-
pulsed untreated DC, were unaffected [50]. In contrast,
Ra ̈𝜄ch-Regué et al. ruled out specific apoptosis of autoreactive
T cells [14]. In addition, tolDC can also initiate immune toler-
ance via the induction or expansion of Treg (i.e., “infectious





-treated DC are able to induce antigen-specific
IL-10-secreting Tr1 cells, capable of suppressing proliferation
of responder T cells in vitro [18, 51]. Furthermore, it was





-treated DC and was mediated by PD-
L1 [18] and/or membrane-bound TNF-𝛼 expressed on the
tolDC surface [51]. However, we and others [14, 52] could











-treated DC and T cells.





-treated DC display a semimature phenotype






T cell hyporesponsiveness to myelin-derived antigens. Fur-





-treated DC. Since cryopreservation did not
affect the viability, phenotype, and the allogeneic T cell-




-treated DC, our results
contribute to the large-scale production and the widely




-treated DC. Recent efforts by
the European COST (European Cooperation in Science and
Technology) network A FACTT (action to focus and accele-
rate cell-based tolerance-inducing therapies) have resulted in
initiatives to harmonize tolDC therapy in a cost-effective and
efficient way [53].We expect that the demonstrated feasibility
of the cryopreservation of tolDC in this study is an important
step forward in the field of tolDC vaccination andmay lay the
groundwork for the development of a new form of cellular
immunotherapy for MS and other autoimmune diseases.
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